These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 17324472

  • 1. IgG subclass distribution of autoantibodies in pediatric opsoclonus-myoclonus syndrome.
    Beck S, Fühlhuber V, Krasenbrink I, Tschernatsch M, Kneifel N, Kirsten A, Jaeger C, Kaps M, Preissner KT, Lang B, Rostasy K, Blaes F.
    J Neuroimmunol; 2007 Apr; 185(1-2):145-9. PubMed ID: 17324472
    [Abstract] [Full Text] [Related]

  • 2. New autoantibodies in pediatric opsoclonus myoclonus syndrome.
    Kirsten A, Beck S, Fühlhuber V, Kaps M, Kreutz T, Korfei M, Schmitt S, Preissner KT, Blaes F.
    Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440
    [Abstract] [Full Text] [Related]

  • 3. Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
    Korfei M, Fühlhuber V, Schmidt-Wöll T, Kaps M, Preissner KT, Blaes F.
    J Neuroimmunol; 2005 Dec 30; 170(1-2):150-7. PubMed ID: 16203043
    [Abstract] [Full Text] [Related]

  • 4. Autoantibodies in childhood opsoclonus-myoclonus syndrome.
    Blaes F, Pike MG, Lang B.
    J Neuroimmunol; 2008 Sep 15; 201-202():221-6. PubMed ID: 18687475
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
    Fühlhuber V, Bick S, Kirsten A, Hahn A, Gerriets T, Tschernatsch M, Kaps M, Preissner KT, Blaes F, Altenkämper S.
    J Neuroimmunol; 2009 May 29; 210(1-2):87-91. PubMed ID: 19339060
    [Abstract] [Full Text] [Related]

  • 7. Identification of autoantigens in pediatric opsoclonus-myoclonus syndrome.
    Blaes F, Fühlhuber V, Preissner KT.
    Expert Rev Clin Immunol; 2007 Nov 29; 3(6):975-82. PubMed ID: 20477144
    [Abstract] [Full Text] [Related]

  • 8. Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma.
    Raffaghello L, Conte M, De Grandis E, Pistoia V.
    Eur J Paediatr Neurol; 2009 May 29; 13(3):219-23. PubMed ID: 18571942
    [Abstract] [Full Text] [Related]

  • 9. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.
    Zar T, Tschernatsch M, Hero B, Lang B, Preissner KT, Blaes F.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e176-e179. PubMed ID: 33060390
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Opsoclonus myoclonus ataxia syndrome in Israel].
    Blumkin L, Lerman-Sagie T.
    Harefuah; 2010 Jan 01; 149(1):24-8, 63. PubMed ID: 20422836
    [Abstract] [Full Text] [Related]

  • 12. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.
    Blaes F, Fühlhuber V, Korfei M, Tschernatsch M, Behnisch W, Rostasy K, Hero B, Kaps M, Preissner KT.
    Ann Neurol; 2005 Aug 01; 58(2):313-7. PubMed ID: 15988749
    [Abstract] [Full Text] [Related]

  • 13. Opsoclonus-myoclonus syndrome: a clinicopathological confrontation.
    Baets J, Pals P, Bergmans B, Foncke E, Smets K, Hauman H, Vanderwegen L, Cras P.
    Acta Neurol Belg; 2006 Sep 01; 106(3):142-6. PubMed ID: 17091618
    [Abstract] [Full Text] [Related]

  • 14. Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment.
    Blaes F, Dharmalingam B.
    Expert Rev Neurother; 2016 Jun 01; 16(6):641-8. PubMed ID: 27095464
    [Abstract] [Full Text] [Related]

  • 15. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.
    Rostásy K, Wilken B, Baumann M, Müller-Deile K, Bieber I, Gärtner J, Möller P, Angelini P, Hero B.
    Neuropediatrics; 2006 Oct 01; 37(5):291-5. PubMed ID: 17236108
    [Abstract] [Full Text] [Related]

  • 16. Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
    Fühlhuber V, Bick S, Tschernatsch M, Dharmalingam B, Kaps M, Preissner KT, Blaes F.
    J Neuroimmunol; 2015 Dec 15; 289():182-6. PubMed ID: 26616889
    [Abstract] [Full Text] [Related]

  • 17. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
    Raffaghello L, Fuhlhuber V, Bianchi G, Conte M, Blaes F, Gambini C, Pistoia V.
    J Leukoc Biol; 2013 Jul 15; 94(1):183-91. PubMed ID: 23610147
    [Abstract] [Full Text] [Related]

  • 18. Serum IgG-induced microglial activation enhances neuronal cytolysis via the NO/sGC/PKG pathway in children with opsoclonus-myoclonus syndrome and neuroblastoma.
    Ding X, Yang W, Ren Q, Hu J, Yang S, Han W, Wang J, Wang X, Wang H.
    J Neuroinflammation; 2020 Jun 16; 17(1):190. PubMed ID: 32546235
    [Abstract] [Full Text] [Related]

  • 19. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.
    Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, Planagumà J, Bataller L, Dalmau J, Graus F.
    JAMA Neurol; 2016 Apr 16; 73(4):417-24. PubMed ID: 26856612
    [Abstract] [Full Text] [Related]

  • 20. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.
    Connolly AM, Pestronk A, Mehta S, Pranzatelli MR, Noetzel MJ.
    J Pediatr; 1997 Jun 16; 130(6):878-84. PubMed ID: 9202608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.